Effects of cilostazol on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: A multicenter prospective, randomized, open-label blinded end point trial - Clinical article

Journal of Neurosurgery

Volumn 118, Issue 1, 2013, Pages 121-130

  Senbokuya, Nobuo ^a   Kinouchi, Hiroyuki ^a   Kanemaru, Kazuya ^a   Ohashi, Yasuhiro ^b   Fukamachi, Akira ^b   Yagi, Shinichi ^c   Shimizu, Tsuneo ^c   Furuya, Koro ^d   Uchida, Mikito ^d   Takeuchi, Nobuyasu ^e   Nakano, Shin ^e   Koizumi, Hidehito ^e   Kobayashi, Chikashi ^f   Fukasawa, Isao ^f   Takahashi, Teruo ^g   Kuroda, Katsuhiro ^g   Nishiyama, Yoshihisa ^a   Yoshioka, Hideyuki ^a   Horikoshi, Toru ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b Nasu Neurosurgical Center   (Japan)

^c Kanto Neurosurgical Hospital   (Japan)

^d Suwa Central Hospital   (Japan)

^e Yamanashi Prefectural Central Hospital   (Japan)

^f Department of Neurosurgery   (Japan)

^g SHIZUOKA MEDICAL CENTER   (Japan)

Author keywords

Cerebral vasospasm; Cilostazol; Subarachnoid hemorrhage; Surgical outcome; Vascular disorders

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; FASUDIL;

ADULT; ANEURYSM CLIP; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN ARTERY ANEURYSM RUPTURE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN VASOSPASM; CEREBROSPINAL FLUID DRAINAGE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIGITAL SUBTRACTION ANGIOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; EPIDURAL HEMATOMA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SCREENING; SINUS TACHYCARDIA; SUBARACHNOID HEMORRHAGE;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 3 INHIBITORS; PROSPECTIVE STUDIES; SUBARACHNOID HEMORRHAGE; TETRAZOLES; TREATMENT OUTCOME; VASODILATOR AGENTS; VASOSPASM, INTRACRANIAL;

EID: 84872197756     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2012.9.JNS12492     Document Type: Article

References (50)

1. Bederson JB, Connolly ES Jr, Batjer HH, Dacey RG, Dion JE, Diringer MN, et al: Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 40:994-1025, 2009
2. Birk S, Kruuse C, Petersen KA, Jonassen O, Tfelt-Hansen P, Olesen J: The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 24:1352-1358, 2004
3. Charpentier C, Audibert G, Guillemin F, Civit T, Ducrocq X, Bracard S, et al: Multivariate analysis of predictors of cerebral vasospasm occurrence after aneurysmal subarachnoid hemorrhage. Stroke 30:1402-1408, 1999
4. Chaudhary SR, Ko N, Dillon WP, Yu MB, Liu S, Criqui GI, et al: Prospective evaluation of multidetector-row CT angiography for the diagnosis of vasospasm following subarachnoid hemorrhage: a comparison with digital subtraction angiography. Cerebrovasc Dis 25:144-150, 2008
5. Dankbaar JW, Rijsdijk M, van der Schaaf IC, Velthuis BK, Wermer MJH, Rinkel GJE: Relationship between vasospasm, cerebral perfusion, and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Neuroradiology 51:813-819, 2009
6. Ecker A, Riemenschneider PA: Arteriographic demonstration of spasm of the intracranial arteries, with special reference to saccular arterial aneurysms. J Neurosurg 8:660-667, 1951
7. Eskridge JM, McAuliffe W, Song JK, Deliganis AV, Newell DW, Lewis DH, et al: Balloon angioplasty for the treatment of vasospasm: results of first 50 cases. Neurosurgery 42:510-517, 1998
8. Findlay JM, Kassell NF, Weir BK, Haley EC Jr, Kongable G, Germanson T, et al: A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Neurosurgery 37:168-178, 1995
9. Findlay JM, Weir BK, Kassell NF, Disney LB, Grace MG: Intracisternal recombinant tissue plasminogen activator after aneurysmal subarachnoid hemorrhage. J Neurosurg 75:181-188, 1991
10. Fisher CM, Kistler JP, Davis JM: Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 6:1-9, 1980
11. Frontera JA, Claassen J, Schmidt JM, Wartenberg KE, Temes R, Connolly ES Jr, et al: Prediction of symptomatic vasospasm after subarachnoid hemorrhage: the modified fisher scale. Neurosurgery 59:21-27, 2006
12. Frontera JA, Fernandez A, Schmidt JM, Claassen J, Wartenberg KE, Badjatia N, et al: Defining vasospasm after subarachnoid hemorrhage: what is the most clinically relevant definition? Stroke 40:1963-1968, 2009
13. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, et al: Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 9:147-157, 2000
14. Haley EC Jr, Kassell NF, Torner JC: A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 78:537-547, 1993
15. Haley EC Jr, Kassell NF, Torner JC, Truskowski LL, Germanson TP: A randomized trial of two doses of nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 80:788-796, 1994
16. Hashimoto A, Miyakoda G, Hirose Y, Mori T: Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 189:350-357, 2006
17. Hirashima Y, Kurimoto M, Hori E, Origasa H, Endo S: Lower incidence of symptomatic vasospasm after subarachnoid hemorrhage owing to ruptured vertebrobasilar aneurysms. Neurosurgery 57:1110-1116, 2005
18. Hunt WE, Kosnik EJ: Timing and perioperative care in intracranial aneurysm surgery. Clin Neurosurg 21:79-89, 1974
19. Ito H, Fukunaga M, Suzuki H, Miyakoda G, Ishikawa M, Yabuuchi Y, et al: Effect of cilostazol on delayed cerebral vasospasm after subarachnoid hemorrhage in rats: evaluation using black blood magnetic resonance imaging. Neurobiol Dis 32:157-161, 2008
20. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F: Cilostazol as a unique antithrombotic agent. Curr Pharm Des 9:2289-2302, 2003
21. Kassell NF, Torner JC, Haley EC Jr, Jane JA, Adams HP, Kongable GL: The international cooperative study on the timing of aneurysm surgery. Part 1: overall management results. J Neurosurg 73:18-36, 1990
22. Kinouchi H, Ogasawara K, Shimizu H, Mizoi K, Yoshimoto T: Prevention of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage by intraoperative cisternal fibrinolysis using tissue-type plasminogen activator combined with continuous cisternal drainage. Neurol Med Chir (Tokyo) 44: 569-577, 2004
23. Mizoi K, Yoshimoto T, Takahashi A, Fujiwara S, Koshu K, Sugawara T: Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolytic therapy with tissue-type plasminogen activator. J Neurosurg 78:430-437, 1993
24. Molyneux AJ, Kerr RS, Birks J, Ramzi N, Yarnold J, Sneade M, et al: Risk of recurrent subarachnoid haemorrhage, death, or dependence and standardised mortality ratios after clipping or coiling of an intracranial aneurysm in the International Sub arachnoid Aneurysm Trial (ISAT): long-term follow-up. Lan cet Neurol 8:427-433, 2009
25. Musahl C, Henkes H, Vajda Z, Coburger J, Hopf N: Continuous local intra-arterial nimodipine administration in severe symptomatic vasospasm after subarachnoid hemorrhage. Neu ro surgery 68:1541-1547, 2011
26. Ogihara K, Zubkov AY, Bernanke DH, Lewis AI, Parent AD, Zhang JH: Oxyhemoglobin-induced apoptosis in cultured endothelial cells. J Neurosurg 91:459-465, 1999
27. Okiyama K, Machida T, Fujikawa A, Nagano O, Aoyagi K, Nomura R, et al: [Evaluation of cerebral vasospasm after subarachnoid hemorrhage based on serial 3D-CTA findings.] Surg Cereb Stroke 39:7-13, 2011 (Jpn)
28. Origitano TC, Wascher TM, Reichman OH, Anderson DE: Sustained increased cerebral blood flow with prophylactic hypertensive hypervolemic hemodilution ("triple-H" therapy) after subarachnoid hemorrhage. Neurosurgery 27:729-740, 1990
29. Otawara Y, Ogasawara K, Ogawa A, Sasaki M, Takahashi K: Evaluation of vasospasm after subarachnoid hemorrhage by use of multislice computed tomographic angiography. Neurosurgery 51:939-943, 2002
30. Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, et al: Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 298:636-642, 1989
31. Rankin J: Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J 2:200-215, 1957
32. Sasaki T, Kodama N, Kawakami M, Sato M, Asari J, Sakurai Y, et al: Urokinase cisternal irrigation therapy for prevention of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage: a study of urokinase concentration and the fibrinolytic system. Stroke 31:1256-1262, 2000
33. Sawada M, Hashimoto N, Tsukahara T, Nishi S, Kaku Y, Yoshimura S: Effectiveness of intra-arterially infused papaverine solutions of various concentrations for the treatment of cerebral vasospasm. Acta Neurochir (Wien) 139:706-711, 1997
34. Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, et al: Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 76:571-577, 1992
35. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, et al: Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9:959-968, 2010
36. Shinohara Y, Ogawa A, Suziki N, Katayama Y, Kimura A (eds): [Treatment of delayed cerebral vasospasm, in: Japanese Guidelines for the Management of Stroke 2009.] Tokyo: Kyowa Kikaku, 2009, pp 211-213 (Jpn)
37. Shinohara Y, Yamaguchi T: Outline of the Japanese Guidelines for the Management of Stroke 2004 and subsequent revision. Int J Stroke 3:55-62, 2008
38. Solenski NJ, Haley EC Jr, Kassell NF, Kongable G, Germanson T, Truskowski L, et al: Medical complications of aneurysmal subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants of the Multicenter Cooperative Aneurysm Study. Crit Care Med 23:1007-1017, 1995
39. Suzuki J, Komatsu S, Sato T, Sakurai Y: Correlation between CT findings and subsequent development of cerebral infarction due to vasospasm in subarachnoid haemorrhage. Acta Neurochir (Wien) 55:63-70, 1980
40. Suzuki S, Sayama T, Nakamura T, Nishimura H, Ohta M, Inoue T, et al: Cilostazol improves outcome after subarachnoid hemorrhage: a preliminary report. Cerebrovasc Dis 32:89-93, 2011
41. Tachibana E, Harada T, Shibuya M, Saito K, Takayasu M, Suzuki Y, et al: Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir (Wien) 141:13-19, 1999
42. Teasdale G, Jennett B: Assessment of coma and impaired consciousness. A practical scale. Lancet 2:81-84, 1974
43. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, et al: Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 103:9-17, 2005
44. Vergouwen MD, Vermeulen M, Coert BA, Stroes ES, Roos YB: Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab 28:1761-1770, 2008
45. Voldby B, Enevoldsen EM, Jensen FT: Regional CBF, intraventricular pressure, and cerebral metabolism in patients with ruptured intracranial aneurysms. J Neurosurg 62:48-58, 1985
46. Weidauer S, Lanfermann H, Raabe A, Zanella F, Seifert V, Beck J: Impairment of cerebral perfusion and infarct patterns attributable to vasospasm after aneurysmal subarachnoid hemorrhage: a prospective MRI and DSA study. Stroke 38: 1831-1836, 2007
47. Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK: Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 38:710-713, 2003
48. Yamaguchi-Okada M, Nishizawa S, Mizutani A, Namba H: Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model. Cerebrovasc Dis 28:135-142, 2009
49. Yasunaga K, Mase K: Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease. Arzneimittelforschung 35 (7A):1189-1192, 1985
50. Yoshimoto T, Shirasaka T, Fujimoto S, Yoshidumi T, Yamauchi T, Tokuda K, et al: Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 49:235-241, 2009